Navigation Links
Live Recombinant Adenovirus Vaccine Technique Explored

Researchers at the Johns Hopkins Bloomberg School of Public Health are exploring ways to develop new vaccines for a variety of illnesses using genetically modified adenoviruses, a common cause of respiratory infections. Oral adenovirus vaccines have long been proven to be safe and effective. The researchers believe their process for constructing a replicating live recombinant adenovirus could lead to more economical vaccines that provide longer-lasting disease protection, which would be particularly beneficial for people living in the developing countries where resources are limited. Their research was made available online March 14, 2005, in advance of publication in the Proceedings of the National Academy of Sciences.

“Many vaccines are expensive to manufacture, require trained personnel to administer and multiple doses to provide immunity, which is not feasible for people living in many parts of the world,?explained Gary Ketner, PhD, senior author of the study and professor with the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. “The military developed oral vaccines for adenovirus years ago that safely provide immunity in one dose. We wanted to see if we could combine the safe and easy-to-use qualities of live adenovirus vaccine with the versatility of recombinant adenovirus virus vaccines that are being developed.?/p>

Specifically, Dr. Ketner and his colleagues hope to develop a vaccine for human papillomavirus (HPV) that could be used in the developing world. HPV causes 500,000 cases of cervical cancer each year worldwide. Recombinant HPV vaccines currently in clinical trials may not be ideal in poorer countries because they are expensive and require multiple immunizations.

The Hopkins researchers developed their vaccine prototype using canine oral papillomavirus (COPV), which behaves similarly to HPV. Research by other scientists showed that a vaccine consisting of recombinant HPV major capsid protein (L1) provides effective immunity to HPV infection. Dr. Ketner and his colleagues theorized that a live recombinant adenovirus could be made to express L1 as the virus replicated in the body and thereby create a lasting immune response. The researchers inserted the L1 gene into a live adenovirus such that it would be expressed using the virus' own late-gene expression machinery. L1 is expressed at very high levels in some recombinants.

Dr. Ketner believes that the replicating live recombinant adenovirus model shows promise as a means of developing economical and long-lasting vaccines for many illnesses. Ongoing research is aimed at determining the effectiveness of recombinants in animals.

Additional authors of “Viable adenovirus vaccine prototypes: High-level production of a papillomavirus capsid antigen from the major late transcriptional unit?include Michael Berg, Julie DiFatta and Egbert Hoiczyk of the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. Author Richard Schlegel is with the Department of Pathology at the Georgetown University Medical Center.

Funding was provided by grants from the National Institutes of Health.


'"/>

Source:Johns Hopkins Bloomberg School Of Public Health


Related biology news :

1. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
2. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. New Vaccine To Be Used For First Time In Polio Outbreak Response
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... , March 22, 2017  UBM and ... to announce their extended partnership and the third ... headlined by the 21 st Annual MassMEDIC ... taking place May 3-4, 2017. ... Technology Association (ADVAMED) President and CEO, Scott ...
Breaking Biology Technology: